Phosphate Binder for the Treatment of Hyperphosphatemia

<strong>Background</strong><br>

Hyperphosphatemia is a complication of chronic kidney disease. Patients with renal insufficiency have an abnormal phosphate metabolism that leads to an elevated concentration of phosphate in the blood. In conjunction with calcium imbalance, hyperphosphatemia increases the risk of cardiovascular disease in patients with renal failure. Hyperphosphatemia promotes arterial calcification which increases the risk of myocardial infarction and is therefore a big risk factor for cardiovascular mortality in dialysis patients. Due to the problems of current phosphate binders like poor taste, halitosis, gastro-intestinal complaints and high cost, there is a great demand for novel phosphate binders.<br><br> <strong>Technology</strong><br> We offer a phosphate binder on the basis of maghemite or maghemite/ magnetite. The novel phosphate binder comprises an iron oxide core being coated with carbohydrates e.g. sugar molecules like mannose or fructan. The iron oxide core is less than 20 nm in diameter and shows an inverse spinel structure, which offers a high phosphate binding capacity. <br><br> <strong>Benefits</strong> <ul> <li>Highly improved phosphate binding capacity</li> <li>Well tolerated oral phosphate binder</li> <li>No known side effects</li> <li>Low manufacturing costs</li> <li>Easy to manufacture </li> </ul> <p><strong>IP Rights</strong><br> DE, US patent application (09/2011)<br> PCT patent application <br> <br> <strong>Patent Owner</strong><br> Charité Universitätsmedizin Berlin</p>

Weitere Informationen: PDF

ipal GmbH
Tel.: +49 (0)30/2125-4820

Ansprechpartner
Dr. Dirk Dantz